Medications like Wegovy, Saxenda, and Mounjaro have gained attention for their effectiveness in aiding weight reduction when combined with lifestyle changes.
This article explores the companies offering these treatments, their efficacy, safety profiles, and associated costs.
Companies Offering Weight Loss Injections in the UK
Several pharmaceutical companies and healthcare providers offer weight loss injections:
Wegovy (Semaglutide): Manufactured by Novo Nordisk, Wegovy has been approved by the National Institute for Health and Care Excellence (NICE) for use within the NHS. It is also available through private healthcare providers.
Saxenda (Liraglutide): Also produced by Novo Nordisk, Saxenda is accessible via the NHS for individuals meeting specific criteria and can be obtained privately.
Mounjaro (Tirzepatide): Developed by Eli Lilly, Mounjaro is available through private clinics and online pharmacies in the UK.
Effectiveness of Weight Loss Injections
Clinical studies have demonstrated the efficacy of these medications:
Wegovy: In a 68-week trial, participants experienced an average weight loss of 15.8% of their initial body weight.
Saxenda: The same study reported a mean weight loss of 6.4% over 68 weeks.
Mounjaro: Clinical trials have shown weight reductions ranging from 15% to 20% of initial body weight.
Safety and Side Effects
While effective, these injections may cause side effects, typically mild but diminishing over time:
Common Side Effects: Nausea, diarrhoea, constipation, headache, fatigue, dizziness, stomach pain, and upset stomach.
Serious Risks: Rare but severe side effects can include pancreatitis. Users are advised to consult healthcare professionals for personalised advice and monitoring.
Cost of Weight Loss Injections
The cost varies depending on the medication and provider:
thedietologist.co.uk
Wegovy: NICE lists prices ranging from £124.54 to £175.80 per pack, depending on the dosage.
Saxenda: Approximately £196.20 for a pack of five 3ml pens.
Mounjaro: Prices start from £188.99 per pen.
These treatments may be available on the NHS for individuals meeting specific criteria; otherwise, they can be accessed through private healthcare channels.
However, some local NHS Trusts routinely decline to prescribe weight loss injections on cost grounds, often blaming dubious 'clinical reasons.'
Conclusion
Weight loss injections like Wegovy, Saxenda, and Mounjaro offer promising avenues for individuals struggling with obesity. While they have shown significant effectiveness, it is crucial to consider potential side effects and consult healthcare providers to determine the most appropriate treatment plan. Costs can be substantial, but eligibility for NHS coverage may alleviate financial burdens for some patients.